Incyte Corporation

This study tested a new drug combination (pemigatinib plus pembrolizumab) versus pemigatinib alone or standard care for people with advanced bladder cancer that has a specific genetic change (FGFR3 mutation). The trial was stopped early after enrolling only 7 participants, so res…

This study tested whether adding the experimental drug parsaclisib to the standard treatment ruxolitinib could better shrink enlarged spleens and ease symptoms in people with myelofibrosis, a rare bone marrow cancer. The trial planned to enroll 252 adults with intermediate- or hi…

This study tested a drug called pemigatinib in 111 people with advanced solid tumors that have certain FGFR gene changes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was stopped early, but results may help guide future treatments for t…

This study tested whether adding the drug epacadostat to the approved immunotherapy ipilimumab could help people with advanced melanoma that cannot be removed by surgery or has spread. The study planned to enroll 50 adults aged 18 and older. However, the study was stopped early f…

This study tested a drug called itacitinib in 23 people who developed bronchiolitis obliterans syndrome after a double lung transplant. The goal was to see if the drug was safe and could improve lung function. The study was terminated early, so results are limited.

This early-phase study tested a new drug called INCA00186, alone or with other immunotherapies, in 57 people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to check safety, find the right dose, and see if the drug helps control the disease…

This study tested a drug called itacitinib combined with steroids as a first treatment for moderate to severe chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. It included 155 participants who had received a stem cell transplant. The study wa…

This study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The main goal was to check safety and find the best dose. The trial was terminated early, so results are limited.

This study tested a combination of two drugs, tafasitamab and parsaclisib, in adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal was to see if the combination was safe and effective. The trial was terminated early, but data on side e…

This study tested a new drug called INCB059872 in people with Ewing sarcoma that had returned or stopped responding to standard treatments. The goal was to see if the drug is safe and if it can shrink tumors. The trial was stopped early, so results are limited.

This study was designed to check the safety and how the body handles an experimental drug called INCB000631 in healthy adults. It was a very early (Phase 1) trial that planned to give the drug or a placebo to 24 people aged 19 to 55. The study was terminated early, so results are…